<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7004585/results/search/disease/results.xml">
  <result pre="Research ArticleStudy Protocol Systematic Review Kushenin combined with entecavir for" exact="chronic hepatitis" post="BA protocol for a systematic review and meta-analysis WangYunxiaMDZhangJiayuanMDJinYuxiaMDXiaoXiaoMDZhangQiMM∗[],"/>
  <result pre="ArticleStudy Protocol Systematic Review Kushenin combined with entecavir for chronic" exact="hepatitis" post="BA protocol for a systematic review and meta-analysis WangYunxiaMDZhangJiayuanMDJinYuxiaMDXiaoXiaoMDZhangQiMM∗[],"/>
  <result pre="has reported that there are &amp;gt;240 million patients infected with" exact="chronic hepatitis" post="B (CHB) worldwide. Once patients with CHB start antiviral"/>
  <result pre="reported that there are &amp;gt;240 million patients infected with chronic" exact="hepatitis" post="B (CHB) worldwide. Once patients with CHB start antiviral"/>
  <result pre="and safety of kushenin (KS) combined with entecavir (ETV) for" exact="chronic hepatitis" post="B. Methods: Randomized controlled trials (RCTs) of KS combined"/>
  <result pre="safety of kushenin (KS) combined with entecavir (ETV) for chronic" exact="hepatitis" post="B. Methods: Randomized controlled trials (RCTs) of KS combined"/>
  <result pre="combined with ETV for CHB. PROSPERO registration number: CRD42019124790. Keywords" exact="chronic hepatitis" post="B entecavir kushenin meta-analysis oxymatrine protocol 1 Introduction More"/>
  <result pre="with ETV for CHB. PROSPERO registration number: CRD42019124790. Keywords chronic" exact="hepatitis" post="B entecavir kushenin meta-analysis oxymatrine protocol 1 Introduction More"/>
  <result pre="Introduction More than 240 million people worldwide are suffering from" exact="chronic hepatitis" post="B (CHB).[1] Once antiviral therapy is initiated, patients with"/>
  <result pre="More than 240 million people worldwide are suffering from chronic" exact="hepatitis" post="B (CHB).[1] Once antiviral therapy is initiated, patients with"/>
  <result pre="(t)ide analogues in the treatment of CHB is to inhibit" exact="viral" post="replication and reduce serum Hepatitis B virus DNA (HBV-DNA)"/>
  <result pre="of CHB is to inhibit viral replication and reduce serum" exact="Hepatitis" post="B virus DNA (HBV-DNA) titer. However, its effect on"/>
  <result pre="B virus DNA (HBV-DNA) titer. However, its effect on reducing" exact="hepatitis" post="B virus surface antigen (HBsAg) transcription is very limited.[2]"/>
  <result pre="serum virological indicators, improving drug resistance and delaying the progression" exact="of liver" post="fibrosis. This meta-analysis aims to provide a basis for"/>
  <result pre="virological indicators, improving drug resistance and delaying the progression of" exact="liver fibrosis." post="This meta-analysis aims to provide a basis for clinical"/>
  <result pre="Types of patients Patients with the diagnosis of CHB[8]: positive" exact="hepatitis" post="B virus surface antigen and/or positive serum HBV-DNA for"/>
  <result pre="and/or positive serum HBV-DNA for more than half a year," exact="elevated serum" post="alanine aminotransferase (ALT) level, there is no limitation on"/>
  <result pre="age, sex. Patients who have coinfection with other types of" exact="hepatitis" post="virus, HIV infection, autoimmune hepatitis, drug-induced liver injury, hereditary"/>
  <result pre="Patients who have coinfection with other types of hepatitis virus," exact="HIV infection," post="autoimmune hepatitis, drug-induced liver injury, hereditary liver disease, hepatic"/>
  <result pre="have coinfection with other types of hepatitis virus, HIV infection," exact="autoimmune" post="hepatitis, drug-induced liver injury, hereditary liver disease, hepatic carcinoma,"/>
  <result pre="of hepatitis virus, HIV infection, autoimmune hepatitis, drug-induced liver injury," exact="hereditary" post="liver disease, hepatic carcinoma, and so on will be"/>
  <result pre="hepatitis virus, HIV infection, autoimmune hepatitis, drug-induced liver injury, hereditary" exact="liver disease," post="hepatic carcinoma, and so on will be excluded. 2.2.3"/>
  <result pre="function indicator. Additional outcomes are the effective rate of serum" exact="hepatic fibrosis" post="indicators, drug resistance rate, side effects rate. 2.3 Searching"/>
  <result pre="with text word searching will be performed, search terms include" exact="Hepatitis" post="B, Chronic, CHB, entecavir, baraclude, kushenin, oxymatrine, matrine. The"/>
  <result pre="and personnel (performance bias), blinding of outcome assessment (detection bias)," exact="incomplete" post="outcome data (attrition bias), and selective outcome reporting (reporting"/>
  <result pre="of HBV paired-guide RNA nucleocapsid, and inhibiting the activity of" exact="viral" post="DNA polymerase.[10] It was also been suggested[11] that KS"/>
  <result pre="level, while KS was more effective in reducing serum HBsAg," exact="hepatitis" post="B virus e antigen (HBeAg), and hepatitis B virus"/>
  <result pre="reducing serum HBsAg, hepatitis B virus e antigen (HBeAg), and" exact="hepatitis" post="B virus c antigen (HBcAg) level, which may explain"/>
  <result pre="Author contributions None. Abbreviations: ALT = alanine aminotransferase, CHB =" exact="chronic hepatitis" post="B, CI = confidence interval, ETV = entecavir, HBcAg"/>
  <result pre="contributions None. Abbreviations: ALT = alanine aminotransferase, CHB = chronic" exact="hepatitis" post="B, CI = confidence interval, ETV = entecavir, HBcAg"/>
  <result pre="B, CI = confidence interval, ETV = entecavir, HBcAg =" exact="hepatitis" post="B virus c antigen, HBeAg = hepatitis B virus"/>
  <result pre="entecavir, HBcAg = hepatitis B virus c antigen, HBeAg =" exact="hepatitis" post="B virus e antigen, HBsAg = hepatitis B virus"/>
  <result pre="antigen, HBeAg = hepatitis B virus e antigen, HBsAg =" exact="hepatitis" post="B virus surface antigen, HBV-DNA = Hepatitis B virus"/>
  <result pre="antigen, HBsAg = hepatitis B virus surface antigen, HBV-DNA =" exact="Hepatitis" post="B virus DNA, KS = kushenin, MD = mean"/>
  <result pre="Y, Xiao X, Zhang Q. Kushenin combined with Entecavir for" exact="chronic hepatitis" post="B: A protocol for a systematic review and meta-analysis."/>
  <result pre="Xiao X, Zhang Q. Kushenin combined with Entecavir for chronic" exact="hepatitis" post="B: A protocol for a systematic review and meta-analysis."/>
  <result pre="no conflicts of interest to disclose. References References [1]TangLSYCovertEWilsonEet al.Chronic" exact="Hepatitis" post="B infection: a review. JAMA2018;319:1802–13.29715359 [2]ChevaliezSHézodeCBahramiSet al.Long-term hepatitis B"/>
  <result pre="[1]TangLSYCovertEWilsonEet al.Chronic Hepatitis B infection: a review. JAMA2018;319:1802–13.29715359 [2]ChevaliezSHézodeCBahramiSet al.Long-term" exact="hepatitis" post="B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy:"/>
  <result pre="J Hepatol2013;58:676–83.23219442 [3]TerraultNALokASFMcMahonBJet al.Update on prevention, diagnosis, and treatment of" exact="chronic hepatitis" post="B: AASLD 2018 hepatitis B guidance. Hepatology2018;67:1560–99.29405329 [4]collab: European"/>
  <result pre="Hepatol2013;58:676–83.23219442 [3]TerraultNALokASFMcMahonBJet al.Update on prevention, diagnosis, and treatment of chronic" exact="hepatitis" post="B: AASLD 2018 hepatitis B guidance. Hepatology2018;67:1560–99.29405329 [4]collab: European"/>
  <result pre="prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018" exact="hepatitis" post="B guidance. Hepatology2018;67:1560–99.29405329 [4]collab: European Association for the Study"/>
  <result pre="Liver. EASL 2017 Clinical Practice Guidelines on the management of" exact="hepatitis" post="B virus infection. J Hepatol2017;67:370–98.28427875 [5]ZhangY-BZhanL-QLiG-Qet al.Dimeric Matrine-type alkaloids"/>
  <result pre="2017 Clinical Practice Guidelines on the management of hepatitis B" exact="virus infection." post="J Hepatol2017;67:370–98.28427875 [5]ZhangY-BZhanL-QLiG-Qet al.Dimeric Matrine-type alkaloids from the roots"/>
  <result pre="in serum, immune functions and liver functions of patients with" exact="chronic hepatitis" post="B. Exp Ther Med2017;14:5837–42.29285129 [7]WangYPZhaoWXueRet al.Oxymatrine inhibits hepatitis B"/>
  <result pre="serum, immune functions and liver functions of patients with chronic" exact="hepatitis" post="B. Exp Ther Med2017;14:5837–42.29285129 [7]WangYPZhaoWXueRet al.Oxymatrine inhibits hepatitis B"/>
  <result pre="with chronic hepatitis B. Exp Ther Med2017;14:5837–42.29285129 [7]WangYPZhaoWXueRet al.Oxymatrine inhibits" exact="hepatitis" post="B infection with an advantage of overcoming drug-resistance. Antiviral"/>
  <result pre="hepatitis B. Exp Ther Med2017;14:5837–42.29285129 [7]WangYPZhaoWXueRet al.Oxymatrine inhibits hepatitis B" exact="infection" post="with an advantage of overcoming drug-resistance. Antiviral Res2011;89:227–31.21277330 [8]collab:"/>
  <result pre="Res2011;89:227–31.21277330 [8]collab: Chinese Society of Hepatology and Chinese Society of" exact="Infectious" post="Diseases CMA. The guideline of prevention and treatment for"/>
  <result pre="[8]collab: Chinese Society of Hepatology and Chinese Society of Infectious" exact="Diseases" post="CMA. The guideline of prevention and treatment for chronic"/>
  <result pre="Infectious Diseases CMA. The guideline of prevention and treatment for" exact="chronic hepatitis" post="B: a 2015 update. J Clin Hepatol2015;31:1941–60. [9]GuyattGHOxmanADVistGEet al.GRADE:"/>
  <result pre="Diseases CMA. The guideline of prevention and treatment for chronic" exact="hepatitis" post="B: a 2015 update. J Clin Hepatol2015;31:1941–60. [9]GuyattGHOxmanADVistGEet al.GRADE:"/>
  <result pre="BMJ2008;336:924–6.18436948 [10]XuW-SZhaoK-KMiaoX-Het al.Effect of oxymatrine on the replication cycle of" exact="hepatitis" post="B virusin vitro. World J Gastroenterol2010;16:2028–37.20419842 [11]GaoLMHanYXWangYPet al.Design and"/>
  <result pre="al.Design and synthesis of oxymatrine analogues overcoming drug resistance in" exact="hepatitis" post="B virus through targeting host heat stress cognate 70."/>
 </snippets>
</snippetsTree>
